FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313251722> ?p ?o ?g. }

• W4313251722 abstract "BackgroundOptimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain.MethodsIn an open-label, adaptive platform trial, we randomly assigned hospitalized adults with Covid-19 to low-dose low-molecular-weight heparin thromboprophylaxis or intermediate-dose or low-dose plus aspirin. In response to external evidence, the aspirin intervention was discontinued and a therapeutic-dose arm added. The primary end point was death or the requirement for new organ support by day 28, analyzed with a Bayesian logistic model. Enrolment was closed as a result of operational constraints.ResultsBetween February 2021 and March 2022, 1574 patients were randomly assigned. Among 1526 participants included in the analysis (India, n=1273; Australia and New Zealand, n=138; and Nepal, n=115), the primary outcome occurred in 35 (5.9%) of 596 in low-dose, 25 (4.2%) of 601 in intermediate-dose, 20 (7.2%) of 279 in low-dose plus aspirin, and 7 (14%) of 50 in therapeutic-dose anticoagulation. Compared with low-dose thromboprophylaxis, the median adjusted odds ratio for the primary outcome for intermediate-dose was 0.74 (95% credible interval [CrI], 0.43 to 1.27; posterior probability of effectiveness [adjusted odds ratio<1; Pr], 86%), for low-dose plus aspirin 0.88 (95% CrI, 0.47 to 1.64; Pr, 65%), and for therapeutic-dose anticoagulation 2.22 (95% CrI, 0.77 to 6.20; Pr, 7%). Overall thrombotic and bleeding rates were 0.8% and 0.4%, respectively. There were 10 serious adverse reactions related to anticoagulation strategy, of which nine were grade 1 or 2 across study interventions and one grade 4 episode of retroperitoneal hematoma in a patient receiving intermediate-dose anticoagulation.ConclusionsIn hospitalized non–critically ill adults with Covid-19, compared with low-dose, there was an 86% posterior probability that intermediate-dose, 65% posterior probability that low-dose plus aspirin, and a 7% posterior probability that therapeutic-dose anticoagulation reduced the odds of death or requirement for organ support. No treatment strategy met prespecified stopping criteria before trial closure, precluding definitive conclusions. (Funded by Australian National Health and Medical Research Council or Medical Research Future Fund Investigator and Practitioner Grants and others; ClinicalTrials.gov number, NCT04483960.)" @default.
• W4313251722 created "2023-01-06" @default.
• W4313251722 creator A5001504324 @default.
• W4313251722 creator A5003464090 @default.
• W4313251722 creator A5003569285 @default.
• W4313251722 creator A5003713446 @default.
• W4313251722 creator A5003854400 @default.
• W4313251722 creator A5004756373 @default.
• W4313251722 creator A5005127716 @default.
• W4313251722 creator A5007005479 @default.
• W4313251722 creator A5007696703 @default.
• W4313251722 creator A5008718859 @default.
• W4313251722 creator A5009861962 @default.
• W4313251722 creator A5009932128 @default.
• W4313251722 creator A5011390192 @default.
• W4313251722 creator A5011578372 @default.
• W4313251722 creator A5012779334 @default.
• W4313251722 creator A5014034069 @default.
• W4313251722 creator A5014705449 @default.
• W4313251722 creator A5017221814 @default.
• W4313251722 creator A5018151410 @default.
• W4313251722 creator A5019172506 @default.
• W4313251722 creator A5019364319 @default.
• W4313251722 creator A5020786234 @default.
• W4313251722 creator A5022257611 @default.
• W4313251722 creator A5023103534 @default.
• W4313251722 creator A5025530641 @default.
• W4313251722 creator A5025698064 @default.
• W4313251722 creator A5026139261 @default.
• W4313251722 creator A5029505577 @default.
• W4313251722 creator A5030365613 @default.
• W4313251722 creator A5030550568 @default.
• W4313251722 creator A5034423284 @default.
• W4313251722 creator A5036356340 @default.
• W4313251722 creator A5037159915 @default.
• W4313251722 creator A5037616954 @default.
• W4313251722 creator A5039279077 @default.
• W4313251722 creator A5039613111 @default.
• W4313251722 creator A5040004837 @default.
• W4313251722 creator A5040011900 @default.
• W4313251722 creator A5041930247 @default.
• W4313251722 creator A5042069905 @default.
• W4313251722 creator A5042090044 @default.
• W4313251722 creator A5042310374 @default.
• W4313251722 creator A5042836800 @default.
• W4313251722 creator A5042952865 @default.
• W4313251722 creator A5042980483 @default.
• W4313251722 creator A5045561043 @default.
• W4313251722 creator A5045857950 @default.
• W4313251722 creator A5046361048 @default.
• W4313251722 creator A5048118657 @default.
• W4313251722 creator A5048415725 @default.
• W4313251722 creator A5048620680 @default.
• W4313251722 creator A5048819373 @default.
• W4313251722 creator A5049679733 @default.
• W4313251722 creator A5050063734 @default.
• W4313251722 creator A5051380152 @default.
• W4313251722 creator A5052270831 @default.
• W4313251722 creator A5052910151 @default.
• W4313251722 creator A5053833894 @default.
• W4313251722 creator A5055221150 @default.
• W4313251722 creator A5055323619 @default.
• W4313251722 creator A5056126732 @default.
• W4313251722 creator A5056996826 @default.
• W4313251722 creator A5057299128 @default.
• W4313251722 creator A5058005775 @default.
• W4313251722 creator A5058731075 @default.
• W4313251722 creator A5060096438 @default.
• W4313251722 creator A5060654566 @default.
• W4313251722 creator A5060990423 @default.
• W4313251722 creator A5063084180 @default.
• W4313251722 creator A5063116837 @default.
• W4313251722 creator A5063546488 @default.
• W4313251722 creator A5063814613 @default.
• W4313251722 creator A5065920869 @default.
• W4313251722 creator A5066380634 @default.
• W4313251722 creator A5067450316 @default.
• W4313251722 creator A5068317146 @default.
• W4313251722 creator A5069789773 @default.
• W4313251722 creator A5070454775 @default.
• W4313251722 creator A5073224659 @default.
• W4313251722 creator A5073695706 @default.
• W4313251722 creator A5074130026 @default.
• W4313251722 creator A5076710103 @default.
• W4313251722 creator A5077282885 @default.
• W4313251722 creator A5077404933 @default.
• W4313251722 creator A5077979125 @default.
• W4313251722 creator A5078081178 @default.
• W4313251722 creator A5078744218 @default.
• W4313251722 creator A5079113626 @default.
• W4313251722 creator A5079464340 @default.
• W4313251722 creator A5080135750 @default.
• W4313251722 creator A5084027827 @default.
• W4313251722 creator A5084703885 @default.
• W4313251722 creator A5087299636 @default.
• W4313251722 creator A5089722288 @default.
• W4313251722 creator A5090245300 @default.
• W4313251722 creator A5090422830 @default.
• W4313251722 creator A5090502067 @default.
• W4313251722 creator A5090998567 @default.

• next